Modern treatment of short bowel syndrome

Palle B Jeppesen

doi:10.1097/MCO.0b013e328363bce4

Modern treatment of short bowel syndrome

17 Citationer (Scopus)

Abstract

Recently, the US Food and Drug Administration and the European Medicines Agency approved the glucagon-like peptide 2 analogue, teduglutide, for the treatment of short bowel syndrome (SBS), and this review describes the physiological basis for its clinical use.

Originalsprog	Engelsk
Tidsskrift	Current Opinion in Clinical Nutrition and Metabolic Care
Vol/bind	16
Udgave nummer	5
Sider (fra-til)	582-7
Antal sider	6
ISSN	1363-1950
DOI	https://doi.org/10.1097/MCO.0b013e328363bce4
Status	Udgivet - sep. 2013

Adgang til dokumentet

10.1097/MCO.0b013e328363bce4

Citationsformater

@article{fb3d70db479d4024a979f17606c15a53,

title = "Modern treatment of short bowel syndrome",

abstract = "Recently, the US Food and Drug Administration and the European Medicines Agency approved the glucagon-like peptide 2 analogue, teduglutide, for the treatment of short bowel syndrome (SBS), and this review describes the physiological basis for its clinical use.",

author = "Jeppesen, {Palle B}",

year = "2013",

month = sep,

doi = "10.1097/MCO.0b013e328363bce4",

language = "English",

volume = "16",

pages = "582--7",

journal = "Current Opinion in Clinical Nutrition and Metabolic Care",

issn = "1363-1950",

publisher = "Lippincott Williams and Wilkins",

number = "5",

}

TY - JOUR

T1 - Modern treatment of short bowel syndrome

AU - Jeppesen, Palle B

PY - 2013/9

Y1 - 2013/9

N2 - Recently, the US Food and Drug Administration and the European Medicines Agency approved the glucagon-like peptide 2 analogue, teduglutide, for the treatment of short bowel syndrome (SBS), and this review describes the physiological basis for its clinical use.

AB - Recently, the US Food and Drug Administration and the European Medicines Agency approved the glucagon-like peptide 2 analogue, teduglutide, for the treatment of short bowel syndrome (SBS), and this review describes the physiological basis for its clinical use.

U2 - 10.1097/MCO.0b013e328363bce4

DO - 10.1097/MCO.0b013e328363bce4

M3 - Journal article

C2 - 23924950

SN - 1363-1950

VL - 16

SP - 582

EP - 587

JO - Current Opinion in Clinical Nutrition and Metabolic Care

JF - Current Opinion in Clinical Nutrition and Metabolic Care

IS - 5

ER -

Modern treatment of short bowel syndrome

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater